SWTX Price Prediction Next Week
Analysis and Insights
News Sentiment and Recent Events:
Insider Trading Activity: The Chief Operating Officer of SpringWorks Therapeutics (SWTX) sold 400 shares, marking the 29th insider sale in six months without any purchases. This indicates a bearish sentiment among insiders.
Potential Takeover Rumors: SWTX stock rose after withdrawing from an investor conference amid rumors of a takeover by Merck KGaA, but dipped when Merck didn't address the deal in their earnings call, creating market uncertainty.
Options Trading Activity: High call option volume, particularly for the $24 strike expiring April 17, suggests some investor optimism about potential upside.
Technical Analysis:
- RSI: Currently at 49.53, indicating a neutral position, not in overbought or oversold territory.
- MACD: The MACD line is slightly above the signal line, indicating a weak bullish signal.
- Fibonacci Levels: Resistance at $55.34 (R1) and support at $47.49 (S1), with the stock currently near the pivot point of $51.42.
Real-Time Price and Volume:
- Current Price: $49.78 (as of 2025-03-17)
- Volume: 1,102,742 shares traded today, indicating moderate trading activity.
Conclusion:
Given the mixed news sentiment, technical indicators, and recent price action, SWTX is expected to trade within a narrow range next week. The stock is likely to face resistance at $55.34 and support at $47.49.
Prediction: The stock price of SWTX is expected to decline slightly to $48.50 next week.
Recommendation: Sell SWTX at current levels, as the potential upside appears limited compared to the downside risk.
SWTX Similar Chart Price Prediction
The price of SWTX is predicted to go up -4.64%, based on the high correlation periods with CASY. The similarity of these two price pattern on the periods is 97.41%.
SWTX
CASY
Down: -4.64%Similarity: 97.41%
SWTX Revenue Forecast
SWTX EPS Forecast
SWTX FAQs
What is SWTX revenue forecast for next quarter？
What is SWTX eps forecast for next quarter？
SWTX Analyst's Forecast
David Nierengarten
Wedbush
Buy
2025-02-12
Price Target
$77
Upside
+34.08%
Wedbush raised the firm's price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares following the Food and Drug Administration's approval for Gomekli in adult and pediatric patients with NF-1-PN tumors and disclosure of a wholesale acquisition cost of $206.25 per mg. The company estimates an average cost of treatment of about $22,000 per month for pediatric and $30,000 for adults in the U.S. The firm had previously estimated a net monthly price of $19,000. Wedbush's new Gomekli worldwide estimates, which assume an EU approval in late 2025, are $37M, $192M, $432M, and $859M in the years 2025-2028. The firm believes that approval was likely one of the conditions for Merck KGaA (MKGAY) to make an "official" offer and expects that to come in the near-term.
Cory Kasimov
Evercore ISI Group
Buy
2024-11-20
Price Target
$60
Upside
+60.26%
